Spero Therapeutics, Inc., a biopharmaceutical company located in Cambridge, Massachusetts, has announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on May 15th, after the market closes. The company is committed to discovering and developing innovative treatments for rare diseases as well as multi-drug resistant (MDR) bacterial infections.
One of Spero Therapeutics’ lead product candidates, SPR720, is being developed as an oral first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), with a Phase 2A proof of concept study currently underway. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections.
Another investigational oral drug being tested by Spero Therapeutics is tebipenem HBr, which is being studied in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis. Spero Therapeutics has granted GSK an exclusive license to commercialize tebipenem HBr in all territories except for certain Asian territories.
SPR206 is another innovative, investigational IV-administered direct-acting next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens in preclinical studies. An IND application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information about Spero Therapeutics and their pipeline, interested parties can visit their website at https://sperotherapeutics.com. For investor relations, contact Ashley R. Robinson at LifeSci Advisors, LLC at arr@lifesciadvisors.com or (617) 775-5956
